Denosumab more effective than Fosamax in late-stage trial

Postmenopausal women treated with Amgen's denosumab showed about 80% more improvement in bone mass at the hip compared with those who took Merck & Co.'s Fosamax, according to results from a head-to-head trial. The results from the Phase III study follow a late-stage study held in February, which found that twice-yearly injections of denosumab boosted bone mineral density.

View Full Article in:

Forbes · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA